Light and Shadow of Na-Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Points for Improvement Based on Our Clinical Experience

Table 1

Background of target patients at starting treatment.

Patients (n = 236)※
※ Patients have been taking SGLT2 inhibitors alone or with the other antidiabetic drugs for at least two years
HbA1c (glico hemoglobin A1c)	9.1 ± 1.7	%
Sex (M/F)	152/84
Age	61.4 ± 12.4	years
Male	61.6 ± 12.9	years
Female	61.0 ± 11.4	years
BMI (body mass index)	27.1 ± 5.2	kg/m^2
Male	26.6 ± 5.1	kg/m^2
Female	28.0 ± 5.2	kg/m^2
Hct (hematocrit)	43.0 ± 4.2	%
TP (total protein)	7.50 ± 0.48	g/dL
ALB (albumin)	4.19 ± 0.40	g/dL
AST (aspartate aminotransferase)	27.4 ± 17.2	U/L
ALT (alanine aminotransferase)	33.1 ± 23.8	U/L
γ-GTP (γ-glutamyl transpeptidase)	49.7 ± 51.4	U/L
TG (triglyceride)	186.8 ± 119.0	mg/dL
HDL-C (HDL-cholesterol)	51.6 ± 16.3	mg/dL
LDL-C (LDL-cholesterol)	118.1 ± 35.3	mg/dL
BUN (urea nitrogen)	16.62 ± 5.48	mg/dL
Cre (creatinine)	0.766 ± 0.255	mg/dL
BUN/Cre (BUN Cre ratio)	23.0 ± 7.0
eGFR (estimated glomerular filtration rate)	81.0 ± 27.8	mL/min/1.73 m^2
UA (uric acid)	5.63 ± 1.47	mg/dL
Na (sodium)	139.5 ± 2.6	mmol/L
K (potassium)	4.30 ± 0.41	mmol/L
	Mean ± SD

Marks are items used as explanatory variables in logistic regression analysis.